Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 7, 2015Expert Opinion on Drug Safety

Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events

View Full Paper
Ask AI
Bookmark
Share

Authors

DYDaisuke YabeKyoto UniversityRNR NishikinoJapan Clinical Cancer Research OrganizationMKMakiko KanekoToho University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yabe et al. (2015) studied this question.

synapsesocial.com/papers/69dccf1ac099bcfdbb133d8bhttps://doi.org/10.1517/14740338.2015.1034105
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients2014 · 1,145 citations
  2. 2Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover2012 · 684 citations
  3. 3Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production2014 · 797 citations
  4. 4Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients2014 · 70 citations
  5. 5Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes2013 · 906 citations